-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.4979 in Restless Legs Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1.4979 in Restless Legs Syndrome Drug Details: BP-1.4979 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OMS-527 in Smoking Cessation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OMS-527 in Smoking Cessation Drug Details: OMS-527 is under development for the treatment of movement...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OMS-527 in Alcohol Addiction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OMS-527 in Alcohol Addiction Drug Details: OMS-527 is under development for the treatment of movement...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMB-101 in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMB-101 in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Drug Details:BMA-101 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NOE-115 in Depression
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NOE-115 in Depression Drug Details: NOE-115 is under development for the treatment of atypical depression...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ketamine in Addictive Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ketamine in Addictive Disorders Drug Details: Ketamine is under development for the treatment of alcohol...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ketamine in Pathological Gambling
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ketamine in Pathological GamblingDrug Details:Ketamine is under development for the treatment of alcohol use disorder (AUD)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMB-101 in Seizures
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMB-101 in Seizures Drug Details:BMA-101 is under development for the treatment of undisclosed seizure disorder, Dravet...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMB-101 in Opium (Opioid) Addiction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMB-101 in Opium (Opioid) Addiction Drug Details:BMA-101 is under development for the treatment of undisclosed seizure...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMB-101 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMB-101 in Alzheimer's Disease Drug Details:BMA-101 is under development for the treatment of undisclosed seizure disorder,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OMS-527 in Substance (Drug) Abuse
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OMS-527 in Substance (Drug) Abuse Drug Details: OMS-527 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Centanafadine Sr in Major Depressive Disorder
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Centanafadine Sr in Major Depressive Disorder Drug Details:Centanafadine SR (EB-1020) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANS-6637 in Substance (Drug) Abuse
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANS-6637 in Substance (Drug) Abuse Drug Details:ANS-6637 (GS-6637) is under development for the treatment of cocaine,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Centanafadine SR in Attention Deficit Hyperactivity Disorder (ADHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Centanafadine SR in Attention Deficit Hyperactivity Disorder (ADHD) Drug Details: Centanafadine SR (EB-1020) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Metyrapone + Oxazepam) in Substance (Drug) Abuse
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Metyrapone + Oxazepam) in Substance (Drug) Abuse Drug Details:EMB-001 is under development for the treatment of...
-
Product Insights
![]()
Eat JUST/ Proterra Invest – Plant-Based Protein Production Facility – Central Singapore
Equip yourself with the essential tools needed to make informed and profitable decisions with our Eat JUST/ Proterra Invest - Plant-Based Protein Production Facility - Central Singapore report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Saxenda in Smoking Cessation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Saxenda in Smoking CessationDrug Details:Liraglutide (Saxenda) an analog of human GLP-1 acts as an antiobesity agent....
-
Analyst Opinions
![]()
Future Prospects for Cultured Meat – Regulatory Approval, Challenges, Opportunities, Key Players and Case Studies
Future Prospects for Cultured Meat Report Overview Cultured meat (including cultivated and lab-grown) has huge potential and is gaining more regulatory approval. However, the cost, scalability, health, safety, sustainability, and ethics all fall short compared to other protein sources at present. For this purpose, Cultured meat must maintain momentum through promotion as the product that will fill the gap in the meat and meat alternatives market. The appeal of cultured meat among consumers is consequently low, but disruptive start-ups are...
-
Sector Analysis
New![]()
United Kingdom (UK) Food and Grocery Retailing Market Size, Trends, Consumer Attitudes and Key Players to 2027
The UK Food & Grocery report offers a comprehensive insight into the Food & Grocery market in the UK, analysing the sector, the major players, the main trends, and consumer attitudes, as well as providing market forecasts out to 2027. The total UK food & grocery market is forecast to be worth £185.7bn in 2023, up 8.0% on the previous year. High food inflation and volume declines beginning in 2022 have severely impacted consumer shopping habits and weakened the position...
-
Sector Analysis
![]()
United Kingdom (UK) Home Outdoor Furniture Market Trends, Analysis, Consumer Dynamics and Spending Habits
The UK: Home Category Data, The Consumer - Outdoor furniture 2023 report offers a comprehensive insight into consumer attitudes in the UK outdoor furniture market. The report focuses on seven key subcategories: overall outdoor furniture, decorative accessories, dining furniture, lounging furniture, shelter, outdoor lighting, and outdoor heating. Consumer data is based on our 2023 UK outdoor eating survey, using a panel of 2,000 nationally representative consumers.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.